Maximize Your Visibility with a Product Theater
Product Theaters are turnkey, 45-minute marketing presentations about your company’s products or services. These sessions do not offer CME credit; rather, they give exhibitors the freedom to create a presentation centered on their company’s products.
Only DDW industry supporters who have secured a booth are eligible to apply for a slot for a product theater, subject to availability and adherence to all published guidelines.
Schedule
DDW Theaters are located in the Exhibit Hall. Below is the current schedule of Product Theaters. More information can be found in the DDW Meeting Planner.
Sunday, May 19, 2024
| 9:30 a.m. | Adding on Second-Line Therapy to Help Change the Course of Treatment in PBC |
| Supported by Intercept Pharmaceuticals Inc. | |
| 9:30 – 10:15 a.m. | |
| DDW Theater 1 | |
| 10:20 a.m. | VELSIPITY (etrasimod): Come learn about an Rx treatment option from Pfizer |
| Supported by Pfizer | |
| 10:20 – 11:05 a.m. | |
| DDW Theater 2 | |
| 10:45 a.m. | Optimizing Management of Constipation and Abdominal Symptoms in Adult IBS-C Patients. Time to have a deeper conversation with your adult patients with IBS-C. |
| Supported by AbbVie/Ironwood Pharmaceuticals | |
| 10:45 – 11:30 a.m. | |
| DDW Theater 1 | |
| 11:35 a.m. | Learn About Omvoh: Some Discoveries Are Too Urgent to Ignore |
| Supported by Lilly USA | |
| 11:35 a.m. – 12:20 p.m. | |
| DDW Theater 2 | |
| 12:00 p.m. | Advancements in the Evaluation and Treatment of Esophageal Disorders |
| Supported by Medtronic | |
| 12:00 – 12:45 p.m. | |
| DDW Theater 1 | |
| 12:50 p.m. | Head-to-Head in CD: Comparing Head-to-Head Study Results for the Treatment of Crohn’s Disease |
| Supported by AbbVie | |
| 12:50 – 1:35 p.m. | |
| DDW Theater 2 | |
| 1:15 p.m. | Eosinophilic Esophagitis: Discover a Treatment Option for Your Patients |
| Supported by Sanofi and Regeneron | |
| 1:15 – 2:00 p.m. | |
| DDW Theater 1 | |
| 2:05 p.m. | Evidence Beyond Clinical Trials: STELARA® Real-world Evidence in Bio-Naïve Adults With Moderately to Severely Active Crohn’s Disease (CD) or Ulcerative Colitis (UC) |
| Supported by Johnson & Johnson | |
| 2:05 – 2:50 p.m. | |
| DDW Theater 2 | |
| 2:30 p.m. | Discover a Different Mechanism of Action to Treat Adults With IBS-C: A Case Based Discussion |
| Supported by Ardelyx | |
| 2:30 – 3:15 p.m. | |
| DDW Theater 1 | |
| 3:20 p.m. | One Treatment with Two Options: Route of Administration Flexibility with ENTYVIO (vedolizumab) |
| Supported by Takeda Pharmaceuticals U.S.A., Inc. | |
| 3:20 – 4:05 p.m. | |
| DDW Theater 2 |
Monday, May 20, 2024
| 9:30 a.m. | Discover a New Option that is Available for Patients with NASH with Liver Fibrosis |
| Supported by Madrigal Pharmaceuticals | |
| 9:30 – 10:15 a.m. | |
| DDW Theater 1 | |
| 10:20 a.m. | All About the ENTYVIO (vedolizumab) Subcutaneous Pen |
| Supported by Takeda Pharmaceuticals U.S.A., Inc. | |
| 10:20 – 11:05 a.m. | |
| DDW Theater 2 | |
| 10:45 a.m. | A Proactive Way to Treat IBS-D: Postmarketing Information and Phase 4 Data |
| Supported by AbbVie/Ironwood Pharmaceuticals | |
| 10:45 – 11:30 a.m. | |
| DDW Theater 1 | |
| 11:35 a.m. | From diagnosis to management in eosinophilic esophagitis: The clinical consequences of a chronic, progressive disease |
| Supported by Sanofi and Regeneron Pharmaceuticals, Inc | |
| 11:35 a.m. – 12:20 p.m. | |
| DDW Theater 2 | |
| 12:00 p.m. | The Evolution of CRC Screening: how scientific rigor, commitment to innovation, and patient navigation will shape clinical practice |
| Supported by Exact Sciences | |
| 12:00 – 12:45 p.m. | |
| DDW Theater 1 | |
| 12:50 p.m. | The Power to Help Heal and Maintain Healing of Erosive GERD in Adults |
| Supported by Phathom Pharmaceuticals | |
| 12:50 – 1:35 p.m. | |
| DDW Theater 2 | |
| 1:15 p.m. | UC Results: Exploring Clinical Outcomes and Long-term Safety of a JAK Inhibitor for Patients with UC |
| Supported by AbbVie | |
| 1:15 – 2:00 p.m. | |
| DDW Theater 1 | |
| 2:05 p.m. | What’s Next in EoE: Taking a Deep Dive into a New Therapeutic Option |
| Supported by Takeda Pharmaceuticals U.S.A., Inc. | |
| 2:05 – 2:50 p.m. | |
| DDW Theater 2 | |
| 2:30 p.m. | An Investigational New MOA that Can Stabilize the Inflammatory Response in Ulcerative Colitis |
| Supported by Abivax | |
| 2:30 – 3:15 p.m. | |
| DDW Theater 1 | |
| 3:20 p.m. | A Treatment Option for Certain Adults With Advanced Gastric or GEJ Adenocarcinoma |
| Supported by Merck & Co., Inc. | |
| 3:20 – 4:05 p.m. | |
| DDW Theater 2 |
Tuesday, May 21, 2024
| 9:30 a.m. | Breaking The Cycle of Recurrence |
| Supported by Nestlé Health Science I Seres Therapeutics, Inc | |
| 9:30 – 10:15 a.m. | |
| DDW Theater 1 | |
| 10:20 a.m. | Attention on MASH: Exploring the Role of Metabolic Dysfunction in a Chronic Liver Disease |
| Supported by Novo Nordisk | |
| 10:20 – 11:05 a.m. | |
| DDW Theater 2 | |
| 10:45 a.m. | Identifying and Managing Risk of Disease Progression in Patients with PBC |
| Supported by Ipsen Biopharmaceuticals, Inc. | |
| 10:45 – 11:30 a.m. | |
| DDW Theater 1 | |
| 11:35 a.m. | From epidemiology to endpoints: evolving perspectives on eosinophilic esophagitis (EoE) medical symposium |
| Supported by Bristol Myers Squibb | |
| 11:35 a.m. – 12:20 p.m. | |
| DDW Theater 2 | |
| 12:00 p.m. | BEyond the Diagnosis: Personalized, Precision Medicine in the Management of Barrett’s Esophagus |
| Supported by Castle Biosciences | |
| 12:00 – 12:45 p.m. | |
| DDW Theater 1 | |
| 12:50 p.m. | Understanding Zymfentra: The first and only subcutaneous infliximab offering a new therapeutic approach in CD and UC maintenance |
| Supported by Celltrion, Inc. | |
| 12:50 – 1:35 p.m. | |
| DDW Theater 2 |
Only a Few Slots Remaining!
If you are interested in booking a Product Theater for DDW, please reach out to our account managers below. If you are not currently an industry supporter, you will be required to secure booth space before you will be able to secure a Product Theater.
Companies #-G:
Nia Murphy
Account Manager
Industry Sales and Operations
301-941-9789 | [email protected]
Companies H-Z:
Tessa Ayala
Account Manager
Industry Sales and Operations
301-657-2176 | [email protected]
Related Opportunities
Satellite Symposia
Industry Supporters can host educational programs before or after DDW scientific sessions, often offering CME to participants.
In-Conjunction With Meetings
ICWs are meetings and events arranged by exhibitors, third-party planners, educational institutions or other non-profit organizations.
Book Your Space
Exceed business goals by exposing your company to key decision makers in GI. The Exhibit Hall will be open May 19-21, 2024.
